Industry Newssurgical roboticsmedical devicesprocept bioroboticsanalyst coverage
Procept Biorobotics Garners Bullish Analyst Coverage
7.0
On December 12, UBS analyst Danielle Antalffy initiated coverage of Procept Biorobotics Corp. (NASDAQ:PRCT) with a Buy rating and a $62 target, implying roughly 93% upside from current levels. As of Dec. 19, 10 analysts covered the stock with 80% Buys and a one-year average target of $51.75 (about 61% upside); Antalffy expects profitability by 2027 as utilization and margins expand.
Key Points
- 1Initiates coverage with Buy and $62 target, implying roughly 93% upside potential
- 2Highlights expected profitability by 2027 via higher utilization, margin expansion, and cost efficiencies
- 3Signals opportunity for investors as consensus average target $51.75 suggests about 61% upside
Scoring Rationale
Official UBS initiation and concrete targets raise investor relevance; limited novelty and industry-specific scope constrain broader impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
